# SAB Biotherapeutics, Inc.: overview SABS · Nasdaq · CIK 1833214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sabs.md) · [Financials](/companies/sabs/financials.md) · [Filings](/companies/sabs/filings.md) · [Insiders](/companies/sabs/insiders.md) Latest reported revenue: [$114.7k](/filings/0001833214-26-000003.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 9, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001833214-26-000003). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0 d](/filings/0001193125-25-280572.md) | [0.1 d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(8726.3%) d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | [(9934.5%) d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.12)](/filings/0001193125-25-280572.md) | not reported | [(0.56)](/filings/0001193125-26-218195.md) | [(1.09)](/filings/0001193125-26-336783.md) | [(0.21)](/filings/0001193125-25-280572.md) | not reported | [(0.35)](/filings/0001193125-26-218195.md) | [(0.28)](/filings/0001193125-26-336783.md) | | Free cash flow | $m | [(6.4) d](/filings/0001193125-25-280572.md) | [(9.6) d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | [(15.3)](/filings/0001193125-26-218195.md) | [(11.4) d](/filings/0001193125-26-336783.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [60.9](/filings/0001437749-23-011640.md) | [23.9](/filings/0000950170-24-038219.md) | [2.2](/filings/0000950170-25-046994.md) | [1.3](/filings/0001833214-26-000003.md) | [0.0](/filings/0001833214-26-000003.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(22.0%)](/filings/0001437749-23-011640.md) | [(121.0%)](/filings/0000950170-24-038219.md) | [(1700.6%)](/filings/0000950170-25-046994.md) | [(3244.9%)](/filings/0001833214-26-000003.md) | not reported | | Net margin | % | [(28.2%)](/filings/0001437749-23-011640.md) | [(78.4%)](/filings/0000950170-24-038219.md) | [(1884.5%)](/filings/0000950170-25-046994.md) | [(2579.0%)](/filings/0001833214-26-000003.md) | not reported | | Diluted EPS | $ per share | [(0.63)](/filings/0001437749-23-011640.md) | [(4.31)](/filings/0000950170-24-038219.md) | [(7.64)](/filings/0000950170-25-046994.md) | [(3.68)](/filings/0001833214-26-000003.md) | [(0.79)](/filings/0001833214-26-000003.md) | | Free cash flow | $m | [(9.0)](/filings/0001437749-23-011640.md) | [(25.6)](/filings/0000950170-24-038219.md) | [(25.3)](/filings/0000950170-25-046994.md) | [(34.6)](/filings/0001833214-26-000003.md) | [(45.7)](/filings/0001833214-26-000003.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sabs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $31.1m | 7,967,207 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $28.5m | 7,299,909 | | Reduced −4,120,091 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $25.8m | 6,627,501 | | Added +195,758 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $25.0m | 6,405,553 | | Added +3,000,000 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $17.2m | 4,401,500 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $14.7m | 3,760,439 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.0m | 3,066,016 | | Added +2,764,690 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $11.6m | 2,972,929 | | Added +479,192 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $11.2m | 2,870,000 | | Reduced −1,531,500 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $10.7m | 2,749,087 | | Reduced −283,610 | ## Recent filings [All 432 filings](/companies/sabs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 12:36 ET | [8-K](/filings/0001193125-26-419769.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-419769 | | 2026-08-10 | 20:27 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000220.md) | Ownership report, active investor, amended | 0001346824-26-000220 | | 2026-08-06 | 11:56 ET | [10-Q](/filings/0001193125-26-336783.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336783 | | 2026-07-07 | 12:15 ET | [8-K](/filings/0001193125-26-296936.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-296936 | | 2026-06-18 | 20:35 ET | [8-K](/filings/0001193125-26-275976.md) | 5.07 Shareholder vote results | 0001193125-26-275976 | | 2026-05-12 | 11:35 ET | [10-Q](/filings/0001193125-26-218195.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218195 | | 2026-05-04 | 20:35 ET | [8-K](/filings/0001193125-26-204125.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-204125 | | 2026-04-30 | 20:45 ET | [DEF 14A](/filings/0001193125-26-197607.md) | Proxy statement, period 2026-06-18 | 0001193125-26-197607 | | 2026-04-22 | 12:13 ET | [8-K](/filings/0001193125-26-168569.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-168569 | | 2026-03-23 | 20:25 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000079.md) | Ownership report, active investor, amended | 0001346824-26-000079 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001833214-26-000003.md), filed Mar 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1833214 - Tickers: SABS, SABSW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.